Clinical Trials
11 trialsNCT03910660 2026-05-15
A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.
BioXcel Therapeutics Inc
Phase 1/2 Completed
NCT04946370 2026-04-21
Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer
Weill Medical College of Cornell University
Phase 1/2 Recruiting
NCT04585750 2026-03-12
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals, Inc
Phase 1/2 Recruiting
NCT07410676 2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2 Recruiting
NCT06400160 2025-11-25
Clinical Trial of TB511 in Advanced Solid Tumors
Twinpig Biolab, Inc.
Phase 1/2 Not yet recruiting
NCT04954599 2025-10-07
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
Maastricht University Medical Center
Phase 1/2 Recruiting
NCT04140526 2025-05-23
PRESERVE-001
OncoC4, Inc.
Phase 1/2 Active not recruiting
NCT02325557 2024-04-02
ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Advaxis, Inc.
Phase 1/2 Completed
NCT06022757 2024-02-23
KEYNOTE F19
Evopoint Biosciences Inc.
Phase 1/2 Recruiting
NCT02499835 2023-08-01
Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer
University of Wisconsin, Madison
Phase 1/2 Completed
NCT05708950 2023-07-13
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
Kineta Inc.
Phase 1/2 Unknown